COMPLEX THERAPY OF CHRONIC PANCREATITIS IN COMORBIDITY WITH CHRONIC VIRAL HEPATITIS C WITH THE USE OF BIOREGULATION THERAPY
DOI:
https://doi.org/10.11603/1811-2471.2021.v.i4.12818Keywords:
chronic pancreatitis, chronic viral hepatitis C, bioregulation therapyAbstract
SUMMARY. Studies have shown the negative impact of comorbid chronic viral hepatitis C (CVHC) on the course of chronic pancreatitis (CP), which was manifested by much more pronounced pathological signs compared to the control group. The article analyzed changes in clinical indicators of patients with CP in combination with CVHC in the process of complex treatment with the use of bioregulation therapy (BRT). The use of complex BRT contributed to a statistically significant increase in the effectiveness of treatment of chronic pancreatitis with CVHC. In recent years, attention has increased to the infectious agent, the impact of which can lead to the development of an inflammatory process in the pancreas. The significant spread of viral hepatitis C among the population, the variety of its off-peak manifestations cause the relevance of the problem.
The aim – to change the clinical indicators of patients with CP in combination with CVHC in the process of complex treatment with the use of BRT.
Material and Methods. 106 patients with CP (among them 72 – with CP in combination with CVHC (I and II groups) and 34 – with isolated CP (group III)) were examined. All patients were prescribed a course of base drugs (analgesics, antispasmolytics, polyspherment drugs, proton pump inhibitors, aluminum-containing antacids, antibacterial drugs, vitamins, hepatoprotectors), and group I (36 patients) – at the same time a course of complex BRT: complex bioregulation corrector of external insufficiency of software (Momordica Compositum: 1 ampoule 2.2 ml intramuscularly 3 times a week №10) and complex bioregulation hepatotropic drug (Hepeel: 1 tab. sublingually 3 times a day for 15–20 minutes before meals or 1 hour after meals during the 1 month). The results of treatment were compared with the data of patients who received only standard drug therapy (group II – 36 patients). Examinations were carried out before and after the course of therapy.
Results. Deepening of external software insufficiency was established in the group of patients with CP with comorbid CVHC: the indicator of fecal elastase-1 is statistically lower compared to the group of patients with isolated CP, which indicates an enzymative insufficiency of medium severity (p<0.05). In the group of patients with CP, external secretory insufficiency of the pancreas outweighed the mild severity. A reliable deterioration in coprogram indicators in the group of patients with CP+CVHC was detected compared to a group of patients with isolated CP (p<0.05). After treatment, improved coprogram results and an increase in fecal elastase-1 levels were achieved.
References
Babak, O.Y., & Kharchenko, N.V. (Eds.) (2012). Ratsionalna diahnostyka i farmakoterapiya zakhvoryuvan orhaniv travlennia [Rational diagnosis and pharmacotherapy of diseases of the digestive system]. Guide "Gastroenterologist". 4th type, processing. and supplement. Kyiv: OO "Doctor-Media" [in Russian].
Pasyeshvyly, L.M., & Envyavnov, A.A. (2001). Rol virusnoy infektsii v porazhenii podzheludochnoy zhelezy u bolnykh ishemicheskoy boleznyu serdtsa [The role of the freaking out infection in the pore-like geles in the pain of the heart]. Vrachebnaya praktika – Medical Practice, 4, 43-45 [in Russian].
Reshetilov, Yu.I., Tokarenko, A.I., Dmitriyeva, S.N., Kuznetsova, L.F., Surmilo, N.N., Protsenko, N.N., ..., & Kremzer, A.A. (2002). Infektsii i ikh mesto sredi drugikh prichin vozniknoveniya pankreatita [Infections and their place among other causes of pancreatitis]. Suchasna hastroenterolohiia – Modern Gastroenterology, 2(8), 24-29 [in Russian].
Gubergrits, N.B., & Lukashevich, G.M. (2002). Sochetannyye zabolevaniya pecheni i podzheludochnoy zhelezy: etiopatogeneticheskiye varianty i printsipy lecheniya [Combined diseases of the liver and pancreas: etiopathogenetic options and principles of treatment]. Suchasna hastroenterolohiia – Modern Gastroenterology, 2(8), 33-37 [in Russian].
Cacoub, P., Comarmond, C., Domont, F., & Savey, L. (2016). Extrahepatic manifestations of chronic hepatitis C virus infection. Ther. Adv. Infect. Dis., 3(1), 3-14.
DOI: 10.1177/2049936115585942.
Virović Jukić, L., & Kralj D. (2017). Extrahepatic manifestations of hepatitis C virus infection. Intech. Open. DOI: 10.5772/intechopen.70728.
Wong, R.J., Saab, S., & Ahmed, A. (2017). Extrahepatic manifestations of hepatitis C virus after liver transplantation. Clin. Liver Dis., 21(3), 595-606. DOI: https://doi.org/10.1016/j.cld.2017.03.013.
El-Serag, H.B., Engels, E.A., Landgren, O., Chiao, E., Henderson, L., Amaratunge, H.C., & Giordano, T.P. (2009). Risk of hepatobiliary and pancreatic cancers following hepatitis C virus infection. Hepatology. DOI: 10.1002/hep.22606.
Babinets, L.S., Shaihen, O.R., Homyn, H.O., & Halabitska, I.M. (2019). Specific aspects of clinical course in case of combination of chronic pancreatitis and concomitant viral hepatitis C. Wiad. Lek. (Warshaw Poland 1960), 72(4), 595-599.
Babinets, L.S., Shaihen, O.R., & Khomyn, H.O. (2018). Kliniko-patohenetychni aspekty khronichnoho pankreatytu v poiednanni z virusnym hepatytom C v ambulatornii praktytsi [Clinical and pathogenetic aspects of chronic pancreatitis in combination with viral hepatitis C in outpatient practice]. Hastroenterolohiya – Gastroenterology, 52(2), 88-92 [in Ukrainian].
Babinets, L.S., Shaihen, O.R., & Khomyn, H.O. (2018). Yakist zhyttia khvorykh na khronichnyi pankreatyt u poiednanni iz virusnym hepatytom C [Quality of life of patients with chronic pancreatitis in combination with viral hepatitis C]. Zdobutky klinichnoyi i eksperymentalnoi medytsyny – Achievements of Clinical and Experimental Medicine, 1, 38-43 [in Ukrainian].
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
